Cover Image
市場調查報告書

全球人體生長荷爾蒙劑市場

Human Growth Hormone Drugs

出版商 Global Industry Analysts, Inc. 商品編碼 252329
出版日期 內容資訊 英文 158 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
全球人體生長荷爾蒙劑市場 Human Growth Hormone Drugs
出版日期: 2017年01月01日 內容資訊: 英文 158 Pages
簡介

本報告提供全球人體生長荷爾蒙劑市場相關調查,市場概要及預測,各地區趨勢,及打入市場的主要企業簡介等彙整資料。

第1章 簡介,調查方法,產品定義

第2章 摘要整理

  • 產業概要
    • 市場預測
    • 重組人體生長荷爾蒙的發展
    • 專利失效在生技仿製藥的登場開啟道路
    • 技術創新席捲產業
    • 市場規模
    • 促進成長要素
    • 生長激素缺乏症的高罹患率
    • hGH置換療法的新適應症
    • 阻礙成長要素
    • 複雜的輸送系統
    • hGH治療的成本高
    • 償付確保的困難
    • 生技仿製藥收益擴大的威脅
    • 目前藥物存在有限的藥理學性差異
  • 市場趨勢與課題
  • 競爭環境
    • 非常整合的市場
    • 主要的已上市hGH產品概要
    • 開發中產品概要 其他
  • 人體生長荷爾蒙:概要
  • 近幾年的產業活動
  • 主要加入企業
    • Eli Lilly and Company
    • Ferring Holding SA
    • Genentech, Inc.
    • GeneScience Pharmaceuticals Co., Ltd.
    • Merck KgaA (Germany)
    • Novo Nordisk A/S
    • Pfizer, Inc.
    • Sandoz International GmbH
  • 全球市場預測

第3章 市場

  • 美國
  • 加拿大
  • 日本
  • 歐洲
  • 亞太地區
  • 其他

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: MCP-7129

This report analyzes the worldwide markets for Human Growth Hormone Drugs in US$ Million. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2015 through 2022. Also, a six-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 28 companies including many key and niche players such as -

Eli Lilly and Company
Ferring Holding SA
Genentech, Inc.
GeneScience Pharmaceuticals Co., Ltd.
Merck KgaA

Table of Contents

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

  • Study Reliability and Reporting Limitations
  • Disclaimers
  • Data Interpretation & Reporting Level
    • Quantitative Techniques & Analytics
  • Product Definitions and Scope of Study

II. EXECUTIVE SUMMARY

1. INDUSTRY OVERVIEW

  • Market Outlook
  • Evolution of Recombinant Human Growth Hormones (hGH)
    • List of Select Approved Prescription Daily-dose hGH Products by Indication
  • Patent Expiry Paves Way for the Emergence of Biosimilars; Impact Remains Small
  • Strong Innovation Drive Takes Hold of the hGH Industry
  • Sizing the Market
  • Key Growth Drivers
  • High Prevalence of Growth Hormone Deficiency Disorders
  • Innovations Hold the Key to Market Growth
  • New Indications for hGH Replacement Therapy
  • Major Growth Restraining Factors
  • Complex Delivery System
  • High Cost of hGH Treatment
  • Difficulty in Securing Reimbursement
  • Biosimilars Threaten Revenue Growth Erosion
  • Limited Pharmacological Differences Exist Among Current Agents

2. MARKET TRENDS & ISSUES

  • Pediatric GHD Rules, while Adult GHD Remains Underserved
    • Table 1: Worldwide Recombinant Human Growth Hormone Market by Indication (2016E): Percentage Breakdown of Value Sales for Adult GHD, Turner Syndrome & Idiopathic Short Stature; Pediatric GHD; and Others (includes corresponding Graph/Chart)
  • Long-Acting hGH Drugs - a Potential Game Changer
  • Select Long-Acting hGH Products in Pipeline by Development Stage
  • Biosimilars Create Little Impact, Further Validation to Expand Indications and Growth
    • Table 2: Worldwide Biosimilar Demand by Product Category (2013): Percentage Breakdown of Value Sales for Epoetina, Granulocyte Colony-Stimulating Factors (G-CSFs), Interferons, Insulins, Low Molecular Weight Heparins (LMWH), Recombinant Human Growth Hormones (rhGHs), and Others (includes corresponding Graph/Chart)
  • Manufacturers Bet on Novel Drug Delivery Technologies
  • Phase IV Studies Necessitated for First Biosimilars
  • Needle-less Drug Delivery Systems to Wipe Out of Syringes
  • Drug Delivery Device Options for Marketed hGH Products
  • Growing Non-Prescription/Off-Label Usage - A Potential Health Hazard
  • Oral hGH Secretagogues - An Alternative to Controversial hGH Injections in Professional Sports
  • Risk of Cancer Necessitates Judicious Use of hGH in Children
  • Dose Titration - A Key to Achieve Enhanced Tolerability
  • Growth Concerns about Prolonged Usage of Growth Hormones

3. COMPETITIVE LANDSCAPE

  • hGH - A Highly Consolidated Market
    • Table 3: Leading Recombinant hGH Products in the Global Market (2015): Annual Sales in US$ Million for Genotropin, Humatrope, Norditropin, Nutropin and Saizen (includes corresponding Graph/Chart)
  • Overview of Select Leading Marketed hGH Products
  • Norditropin
  • Genotropin
  • Humatrope
  • Saizen
  • Omnitrope - the Somatropin Biosimilar
  • Somatropin Biopartners
  • Review of Select hGH Products in Pipeline
  • OPKO's Lagova to be the Earliest of Long-Acting hGHs to Hit the Market
  • Somavaratan Advances Further in Clinical Trials
  • Somapacitan Moves Ahead in Development; Nears Commercial Launch
  • TransCon hGH - the Potential Blockbuster hGH Product in Waiting
    • HanAll's Vitatropin

4. HUMAN GROWTH HORMONE: AN OVERVIEW

  • Key Factors Controlling Natural hGH Secretion
  • Structure of hGH
  • Functions Performed by hGH in the Human Body
  • Benefits of Adequate hGH
  • Effects of Human Growth Hormone Imbalances
  • Hypopituitarism
  • Evolution of Growth Hormone Replacement Therapy
  • Indications for Exogenous hGH Administration
  • Growth Hormone Deficiency (GHD)
    • Symptoms of Adult Growth Hormone Deficiency
  • Idiopathic Short Stature
  • Noonan Syndrome
  • Prader-Willi Syndrome
  • Turner Syndrome
  • Short Stature Homeobox Gene
  • Small for Gestational Age
  • Chronic Renal Insufficiency
  • Short Bowel Syndrome
  • Other Medical Conditions
  • Off-label Applications
  • Contraindications for Somatropin Therapy
  • Safety Review of hGH Therapy
  • Reported Adverse Effects of Inaccurate rhGH Dosages
  • Risks Involved with Pediatric/Adolescent hGH Replacement Therapy
  • Risks Involved with Adult hGH Replacement Therapy

5. RECENT INDUSTRY ACTIVITY

  • NHI Includes JCR Pharmaceuticals's GROWJECT Liquid hGH Formulations in Reimbursement Listing
  • Ascendis Pharma Commences Phase III Trial on TransCon hGH
  • Teijin Inks License Deal with Versartis for Somavaratan
  • JCR Pharmaceuticals Obtains Japanese MHLW Approval for Growject(r) Liquid Formulations
  • Merck Dissolves Merck Serono and Merck Millipore Brands, Relaunches Merck Brand
  • EMD Serono and Aeterna Zentaris Finalize Promotional Services Deal for Saizen
  • Versartis Commences Phase II/III Studies for VRS-317 in Japan
  • Ferring Pharmaceuticals Obtains FDA Clearance for Name Change of Growth Hormone
  • Hanmi Introduces Development-Stage Long Acting hGH
  • Novo Nordisk Obtains FDA Approval for Norditropin(r) FlexPro(r) Prefilled Pen
  • OPKO and Pfizer Ink Agreement for Development of OPKO's Long-acting hGH-CTP
  • Pfizer Announces Positive Results from Phase 3B Study on Genotropin for SGA in Children

6. FOCUS ON SELECT GLOBAL PLAYERS

  • Eli Lilly and Company (US)
  • Ferring Holding SA (Switzerland)
  • Genentech, Inc. (US)
  • GeneScience Pharmaceuticals Co., Ltd. (China)
  • Merck KgaA (Germany)
  • Novo Nordisk A/S (Denmark)
  • Pfizer, Inc. (US)
  • Sandoz International GmbH (Germany)

7. GLOBAL MARKET PERSPECTIVE

    • Table 4: World Recent Past, Current and Future Analysis for Human Growth Hormone Drugs by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 5: World Historic Analysis for Human Growth Hormone Drugs by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)
    • Table 6: World 14-Year Perspective for Human Growth Hormone Drugs by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific, and Rest of World Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)

III. MARKET

1. THE UNITED STATES

  • A. Market Analysis
    • Current & Future Analysis
    • US hGH Market - A Peek into GHD Prevalence and Cost of Treatment
    • Table 7: US Patient Volumes Receiving Growth Hormone Therapy by Indication (2016E): Breakdown of Number of Patients in Thousands for Adult GHD, Pediatric GHD and Other Indications (includes corresponding Graph/Chart)
    • Table 8: US hGH Market by Indication (2016E): Percentage Breakdown of Value Sales for Adult GHD, Idiopathic Short Stature, Pediatric GHD, Turner Syndrome and Others (includes corresponding Graph/Chart)
    • FDA Approvals Clear Way for Treating More Children
      • Major hGH Drugs Available in the US, and FDA Approved Indications
    • US FDA Promotes rhGH Development through Orphan Drug Designation
    • FDA Approval of First Biosimilar
      • Omnitrope Versus Genotropin - A US Perspective
      • FDA Issues First Draft of Guidelines for Biosimilar and Interchangeable Biologicals
      • FDA Regulations Governing hGH Products in the OTC Drugs Market
    • Alarming Increase in Sales of hGH Drugs for Anti-Ageing Therapy
    • Strategic Corporate Developments
    • Select Key Players
  • B. Market Analytics
    • Table 9: The US Recent Past, Current and Future Analysis for Human Growth Hormone Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 10: The US Historic Analysis for Human Growth Hormone Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

2. CANADA

  • Market Analysis
    • Table 11: Canadian Recent Past, Current and Future Analysis for Human Growth Hormone Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 12: Canadian Historic Analysis for Human Growth Hormone Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

3. JAPAN

  • A. Market Analysis
    • Current & Future Analysis
    • Market Overview
    • Table 13: Japanese Patient Volumes Receiving Growth Hormone Therapy by Indication (2016E): Breakdown of Number of Patients in Thousands for Adult GHD, Pediatric GHD and Other Indications (includes corresponding Graph/Chart)
    • Table 14: Japanese hGH Market by Indication (2016E): Percentage Breakdown of Value Sales for Pediatric GHD and Others (includes corresponding Graph/Chart)
    • Competition in the Japanese hGH Market
    • Table 15: Key Players in the Japanese hGH Market (2012, 2014 & 2016): Percentage Breakdown of Value Sales for Eli Lilly, JCR, Novo Nordisk, Pfizer and Others (includes corresponding Graph/Chart)
      • Timeline of Major Approvals for JCR Pharmaceutical's hGH Product Growject
    • Japanese Biosimilar Regulatory Guidelines
    • Sandoz' Omnitrope - the First Biosimilar hGH Launched in Japan
    • Strategic Corporate Developments
  • B. Market Analytics
    • Table 16: Japanese Recent Past, Current and Future Analysis for Human Growth Hormone Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 17: Japanese Historic Analysis for Human Growth Hormone Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

4. EUROPE

  • A. Market Analysis
    • Current & Future Analysis
    • Pediatric GHD - Leading Target Indication for hGH Products
    • Table 18: European Patient Volumes Receiving Growth Hormone Therapy by Indication (2016E): Breakdown of Number of Patients in Thousands for Adult GHD, Pediatric GHD and Other Indications (includes corresponding Graph/Chart)
    • Table 19: European hGH Market by Indication (2016E): Percentage Breakdown of Value Sales for Adult GHD, Pediatric GHD and Others (includes corresponding Graph/Chart)
    • European hGH Market Focuses on Product Differentiation to Revitalize Sales
    • Regulations Pertaining to Biosimilars in the EU
    • Table 20: Adoption Rates for hGH Biosimilar in Major Western Europe Markets: 2016 (includes corresponding Graph/Chart)
    • New Indications Could Drive Growth
  • B. Market Analytics
    • Table 21: European Recent Past, Current and Future Analysis for Human Growth Hormone Drugs by Geographic Region - France, Germany, Italy, UK, Spain, and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 22: European Historic Analysis for Human Growth Hormone Drugs by Geographic Region - France, Germany, Italy, UK, Spain, and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)
    • Table 23: European 14-Year Perspective for Human Growth Hormone Drugs by Geographic Region - Percentage Breakdown of Dollar Sales for France, Germany, Italy, UK, Spain, and Rest of Europe Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)

4a. FRANCE

  • Market Analysis
    • Table 24: French Recent Past, Current and Future Analysis for Human Growth Hormone Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 25: French Historic Analysis for Human Growth Hormone Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

4b. GERMANY

  • A. Market Analysis
    • Current & Future Analysis
    • Strategic Corporate Development
    • Key Players
  • B. Market Analytics
    • Table 26: German Recent Past, Current and Future Analysis for Human Growth Hormone Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 27: German Historic Analysis for Human Growth Hormone Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

4c. ITALY

  • Market Analysis
    • Table 28: Italian Recent Past, Current and Future Analysis for Human Growth Hormone Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 29: Italian Historic Analysis for Human Growth Hormone Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

4d. THE UNITED KINGDOM

  • Market Analysis
    • Table 30: The UK Recent Past, Current and Future Analysis for Human Growth Hormone Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 31: The UK Historic Analysis for Human Growth Hormone Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

4e. SPAIN

  • Market Analysis
    • Table 32: Spanish Recent Past, Current and Future Analysis for Human Growth Hormone Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 33: Spanish Historic Analysis for Human Growth Hormone Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

4f. REST OF EUROPE

  • A. Market Analysis
    • Current & Future Analysis
    • Strategic Corporate Development
    • Select Key Players
  • B. Market Analytics
    • Table 34: Rest of Europe Recent Past, Current and Future Analysis for Human Growth Hormone Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 35: Rest of Europe Historic Analysis for Human Growth Hormone Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

5. ASIA-PACIFIC

  • A. Market Analysis
    • Current & Future Analysis
    • Biosimilar Regulations In Asian Countries
      • South Korea
      • China
      • India
    • Genescience Pharmaceuticals Co., Ltd. - A Leading Chinese Player
  • B. Market Analytics
    • Table 36: Asia-Pacific Recent Past, Current and Future Analysis for Human Growth Hormone Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 37: Asia-Pacific Historic Analysis for Human Growth Hormone Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

6. REST OF WORLD

  • Market Analysis
    • Table 38: Rest of World Recent Past, Current and Future Analysis for Human Growth Hormone Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 39: Rest of World Historic Analysis for Human Growth Hormone Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

COMPETITIVE LANDSCAPE

Back to Top